A randomized trial comparing endovascular and surgical management of ruptured intracranial aneurysms excluded from previous trials.

Objective: Many patients with ruptured intracranial aneurysms (RIAs) underrepresented or excluded from previous randomized controlled trials (RCTs) comparing surgery with endovascular treatment (EVT) are still considered for surgical clipping, but the best management of these patients remains unknown.

Methods: The International Subarachnoid Aneurysm Trial-2 was a randomized trial comparing surgical versus EVT of RIAs considered for surgical clipping, despite the results of previous RCTs, and also eligible for EVT. The primary endpoint was death or dependency according to the modified Rankin Scale score (mRS score > 2) at 1 year.

Detection of OXA-23-producing Proteus mirabilis in Switzerland.

Proteus mirabilis is a Gram-negative bacterium found in the environment and also forms part of the commensal flora in the gastrointestinal tract of both humans and animals. P. mirabilis can cause a wide variety of infections, however it does not harbor any intrinsic β-lactamase genes and as such usually exhibits full susceptibility to β-lactams with the exception of imipenem, to which it is naturally resistant.

Activity of Dimercaptosuccinic Acid in Combination with Carbapenems Against Carbapenem-Resistant .

Carbapenenemase producers, particularly the metallo-β-lactamase (MBL) types in , have emerged as an urgent threat in health care settings. MBLs require zinc at their catalytic site and can be inhibited by dimercaptosuccinic acid (DMSA), a metal chelator known for the treatment of lead and mercury intoxication. Isogenic strains of wild-type and OprD-deleted PA14, were constructed, producing the MBLs VIM-2, NDM-1, SPM-1, IMP-1, and AIM-1, or the non-MBL carbapenemases, GES-5 and KPC-2.